Table 1 Clinical characteristics of the study population
From: Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
Parameter | All (N = 53) | Empa (N = 36) | Placebo (N = 17) |
|---|---|---|---|
Age (years) | 68.5 ± 8.2 | 69.0 ± 8.1 | 67.4 ± 8.7 |
Male sex [no, (%)] | 45 (84.9) | 29 (80.6) | 16 (94.1) |
Weight (kg) | 88.7 ± 13.1 | 87.6 ± 13.8 | 90.8 ± 11.3 |
BMI (kg/m2) | 28.9 ± 3.8 | 28.7 ± 4.0 | 29.2 ± 3.3 |
Office heart rate (bpm) | 66.2 ± 12.2 | 65.8 ± 12.8 | 67.0 ± 11.3 |
Office systolic BP (mmHg) | 124.5 ± 19.7 | 126.3 ± 20.0 | 120.5 ± 18.9 |
Office diastolic BP (mmHg) | 72.4 ± 9.3 | 72.1 ± 9.6 | 72.9 ± 9.0 |
Left ventricular ejection fraction (%) | 38.8 ± 8.6 | 39.8 ± 8.3 | 36.8 ± 9.1 |
NT-pro-BNP (pg/ml) | 506.0 (268.5–1311.0) | 499.0 (293.3–1401.8) | 511.0 (189.0–1194.5) |
Hypertension [no, (%)] | 42 (79.2) | 27 (75) | 15 (88.2) |
Type 2 diabetes [no, (%)] | 13 (24.5) | 10 (27.8) | 3 (17.6) |